Biogen Idec, Inc. (Massachusetts)
14 Cambridge Center
Cambridge
Massachusetts
02142
U.S.A.
Phone:
617-679-2000
Fax:
617-679-2617
|
Biogen Idec (NASDAQ: BIIB), formed in November 2003 from the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation, creates new standards of care in oncology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare.
Two blockbuster drugs lead Biogen Idec’s product lineup, each with current annual net sales of more than $1 billion. The first is RITUXAN(R) (rituximab), which was discovered by IDEC, for the treatment of certain B-cell non-Hodgkin’s lymphomas (NHL) which Biogen Idec co-promotes in the United States with Genentech, AVONEX(R) (Interferon beta-1a), which is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS became the first MS product to achieve $1 billion in sales in 2002.
The company has a pipeline of 10 products in clinical development. Two of these products are in Phase III clinical trials: RITUXAN(R) (rituximab), in partnership with Genentech and F. Hoffman-LaRoche, for the treatment of rheumatoid arthritis and other cancer indications, and ANTEGREN(R) (natalizumab), in partnership with Elan Corporation plc, for the treatment of MS and Crohn's disease.
Biogen Idec is headquartered in Cambridge, Massachusetts and maintains centers of excellence in San Diego, California and Cambridge focused on oncology and immunology. The company has additional offices in Canada, Australia, Japan and throughout Europe. The company currently employs approximately 4,000 people worldwide.
Last Updated: 03-02-04
Email:
Ownership:
Web Site:
Biogen Idec, Inc. (Massachusetts)
Employees:
1700
Symbol: BIIB
|
|
|
Company News |
Biogen Idec, Inc. (Massachusetts) (BIIB)'s (JOBS) Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn't Look So Deadly Anymore
11/19/2009 8:01:11 AM
More...
|
Genentech (South SF) (DNA) (JOBS) and Biogen Idec, Inc. (Massachusetts) (BIIB) (JOBS) Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
11/19/2009 7:26:54 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
11/11/2009 10:07:33 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) to Present at the 2009 Annual Credit Suisse Healthcare Conference
11/10/2009 9:51:46 AM
More...
|
Elan Corporation PLC (ELN) (JOBS), Biogen Idec, Inc. (Massachusetts) (BIIB) (JOBS) Change Tysabri Label Due to PML Risk
11/9/2009 6:57:29 AM
More...
|
EU Agency Reports 24th Case of Biogen Idec, Inc. (Massachusetts) (BIIB)'s (JOBS) Tysabri Infection
10/30/2009 7:11:54 AM
More...
|
Elan Corporation PLC (ELN) and Biogen Idec, Inc. (Massachusetts) (BIIB) Release: Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn’s Disease
10/28/2009 9:47:38 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) (JOBS), Elan Corporation PLC (ELN) (JOBS) Shares Plummet on New Tysabri Review
10/23/2009 9:17:01 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Reports Third Quarter 2009 Results
10/20/2009 9:36:00 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Third-Quarter Profit Tops Expectations
10/20/2009 6:43:03 AM
More...
|
|
|
|